Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Glucocorticoids Promote Breast Cancer Metastases

Insights from the patient-derived xenograft models of breast cancer in mice
27 Mar 2019
Translational Research
Breast Cancer

Researchers from the University Hospital Basel, Switzerland showed cancer site specific phenotypes and increased glucocorticoid receptor activity in distant metastases. In patient-derived xenograft models of breast cancer in mice, an increase in stress hormones during progression or treatment with their synthetic derivatives activates the glucocorticoid receptor, and results in increased metastatic colonization and reduced survival. The findings are published on 13 March 2019 in the Nature.

The authors wrote in study background that mechanisms of metastatic colonization are poorly defined. A clearer understanding of the cellular and molecular processes that underlie both intrapatient tumour heterogeneity and metastasis is needed. 

The glucocorticoid receptor mediates the effects of stress hormones, and of synthetic derivatives of these hormones that are used widely in the clinic as anti-inflammatory and immunosuppressive agents.

The study was based on using transcriptional profiling of tumours and matched metastases in patient-derived xenograft models in mice.

The study team showed that the increase in stress hormones during breast cancer progression results in the activation of the glucocorticoid receptor at distant metastatic sites, increased colonization and reduced survival.

Furthermore, transcriptomics, proteomics and phospho-proteomics studies implicate the glucocorticoid receptor in the activation of multiple processes in metastasis and in the increased expression of kinase ROR1, both of which correlate with reduced survival. The ablation of ROR1 reduced metastatic outgrowth and prolonged survival in preclinical models.

Overall, these results indicate that the activation of the glucocorticoid receptor increases heterogeneity and metastasis. From clinical perspective, the authors interpreted their findings at the way that caution is needed when using glucocorticoids to treat patients with breast cancer who have developed cancer-related complications.

 

Reference

Obradović MMS, Hamelin B, Manevski N, et al. Glucocorticoids promote breast cancer metastasis. Nature 2019; 567:540-544. 

Last update: 27 Mar 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.